Preclinical investigations into 5-Amino-1MQ focus on its selective inhibition of nicotinamide N-methyltransferase (NNMT), an enzyme involved in metabolic regulation and cellular methylation. This overview synthesizes current laboratory literature, biochemical mechanisms, analytical testing standards, and experimental protocols governing 5-Amino-1MQ research.
Preclinical investigations into 5-Amino-1MQ focus on its selective inhibition of nicotinamide N-methyltransferase (NNMT), an enzyme involved in metabolic regulation and cellular methylation. This overview synthesizes current laboratory literature, biochemical mechanisms, analytical testing standards, and experimental protocols governing 5-Amino-1MQ research.
In published preclinical literature, a 5-amino-1mq studie typically evaluates the small-molecule inhibitor 5-amino-1-methylquinolinium (5-Amino-1MQ) for its ability to block nicotinamide N-methyltransferase (NNMT). Laboratory models demonstrate that NNMT inhibition by 5-Amino-1MQ prevents the irreversible methylation of nicotinamide, thereby increasing intracellular NAD+ availability, elevating Sirtuin 1 (SIRT1) activity, and enhancing mitochondrial respiration in metabolic tissue assays.
As a membrane-permeable small molecule, 5-Amino-1MQ has emerged as a novel pharmacophore in structural biology and metabolic research. Unlike traditional peptide ligands that target transmembrane G-protein coupled receptors, 5-Amino-1MQ functions via direct enzymatic inhibition within the cytosol. Researchers examining 5-Amino-1MQ raw material prioritize high-purity syntheses to isolate its specific enzymatic interaction from confounding off-target activity.
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). In metabolic tissues such as white adipose tissue (WAT) and liver parenchymal cells, upregulated NNMT activity acts as a sink for both methyl donors and nicotinamide, depleting the available precursor pool required for the NAD+ salvage pathway.
In vitro enzyme kinetic assays demonstrate that 5-Amino-1MQ acts as a substrate-competitive inhibitor of NNMT. By occupying the active site of NNMT, 5-Amino-1MQ suppresses the generation of 1-MNA. Preclinical studies indicate that suppressing this enzymatic sink preserves intracellular SAM and NAM concentrations, thereby restoring the SAM/SAH ratio—a vital metric in cellular methylation dynamics and epigenetic regulation.
To explore how NNMT inhibition intersects with broader metabolic pathways, researchers frequently consult the comprehensive PX1 research library, which details molecular cascades across various peptide and small-molecule classes.
Nicotinamide adenine dinucleotide (NAD+) is a mandatory coenzyme in cellular redox reactions, serving as an electron carrier in glycolysis, fatty acid beta-oxidation, and the tricarboxylic acid (TCA) cycle. Within murine models of diet-induced obesity, hepatic and adipocyte NNMT expression is significantly elevated, driving a decline in cellular NAD+ levels. A hallmark 5-amino-1mq studie involves quantifying the recovery of intracellular NAD+/NADH ratios following compound administration.
When NNMT is inhibited, available NAM is preferentially funneled into nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the NAD+ salvage pathway. Elevated NAD+ levels subsequently stimulate downstream NAD+-dependent enzymes, primarily Sirtuin 1 (SIRT1) and poly(ADP-ribose) polymerases (PARPs). SIRT1 deacetylates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), activating transcriptomic programs responsible for mitochondrial biogenesis and oxidative phosphorylation.
In vitro oxygen consumption rate (OCR) measurements using extracellular flux analyzers reveal that adipocytes treated with 5-Amino-1MQ exhibit increased basal respiration and spare respiratory capacity. These data indicate that target validation via NNMT inhibitor studies provides critical insights into intracellular bioenergetic reprogramming.
Rodent models of metabolic syndrome have provided the primary foundation for evaluating 5-Amino-1MQ in vivo. In high-fat diet (HFD) fed mice, administration of 5-Amino-1MQ produced measurable reductions in adipocyte volume and overall adiposity without altering total food intake. Researchers attribute this phenotype to enhanced basal metabolic rate secondary to mitochondrial uncoupling and upregulated fatty acid oxidation within white adipose tissue.
Histological analyses of adipose tissue from preclinical models show that 5-Amino-1MQ promotes a 'browning' phenotype in subcutaneous white fat depots. Transcripts for uncoupling protein 1 (UCP1), PGC-1alpha, and cytochrome c oxidase subunit IV (COX4) are significantly elevated in treated cohorts compared to vehicle controls. This suggests that 5-Amino-1MQ induces energy dissipation as heat through thermogenic gene induction.
Furthermore, systemic parameters measured in rodent studies demonstrate improved oral glucose tolerance and enhanced insulin sensitivity. Liver tissue analysis from diet-induced obese mice revealed reduced hepatic triglyceride accumulation, signaling potential utility for studying non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis in vitro.
Beyond adipose tissue, skeletal muscle represents a critical organ system where NNMT expression influences metabolic health and regenerative capacity. In aged or damaged muscle tissue, elevated NNMT activity correlates with impaired satellite cell proliferation and reduced muscle fiber cross-sectional area. In vitro studies using C2C12 myoblasts show that 5-Amino-1MQ treatment restores myogenic differentiation markers, including myogenin and myosin heavy chain expression.
Preclinical data indicate that enhanced NAD+ availability in myotubes treated with 5-Amino-1MQ stimulates mitochondrial turnover via mitophagy and biogenesis. Isolated muscle fiber assays demonstrate increased maximal force generation and resistance to contraction-induced fatigue, suggesting that NNMT inhibition modulates skeletal muscle bioenergetics directly at the cellular level.
Investigating these neuromuscular and metabolic parameters requires consistently pure chemical tools. Laboratories scaling up high-throughput screens often utilize PX1 wholesale ordering to maintain batch uniformity across longitudinal rodent trials.
To contextualize the pharmacological profile of 5-Amino-1MQ, researchers frequently compare its mechanisms against other preclinical agents targeting metabolic pathways. While 5-Amino-1MQ acts intratherapeutically via intracellular enzyme inhibition (NNMT), alternative compounds utilize GPCR activation or nuclear receptor agonism.
For instance, mitochondrial-derived peptides like MOTS-c reagent regulate metabolic homeostasis by translocating to the nucleus during metabolic stress to modulate folate cycle kinetics and AMPK activation. Conversely, synthetic ERR-alpha/gamma agonists such as SLU-PP-332 compound directly upregulate nuclear transcription of oxidative phosphorylation genes. In contrast, multi-receptor incretin mimetics like Retatrutide reference material act extracellularly on GLP-1, GIP, and glucagon receptors to modulate systemic satiety and insulin dynamics in vivo.
This structural and mechanistic divergence highlights why 5-Amino-1MQ is uniquely suited for studies investigating direct cellular methylation, intracellular NAD+ salvage pathways, and selective enzymatic blockades without activating systemic endocrine receptor pathways. A complete catalog of these diverse mechanisms can be explored via the PX1 peptide research hub.
5-Amino-1MQ (C10H11N2+, typically supplied as an iodide or chloride salt) is a small-molecule chemical compound requiring specific handling procedures to preserve chemical stability and biological activity in laboratory settings.
For in vitro assays, dry powder should be stored desiccated at -20 deg C or -80 deg C, protected from direct light exposure. Solubilization characteristics differ significantly from standard hydrophilic peptides: 5-Amino-1MQ exhibits limited solubility in aqueous buffers at neutral pH but dissolves readily in dimethyl sulfoxide (DMSO) at concentrations up to 20-50 mg/mL. stock solutions prepared in DMSO should be aliquoted under inert gas and stored at -80 deg C to minimize freeze-thaw cycles.
When preparing working solutions for cell culture assays, DMSO stock aliquots should be diluted into sterile culture media immediately prior to application, keeping the final organic solvent concentration below 0.1% (v/v) to avoid solvent-induced cytotoxicity. For detailed molecular specifications, researchers can review the NAD+ salvage pathway guide.
Because small-molecule inhibitors are subject to synthetic side-products, unreacted precursors, and counter-ion variability, rigorous analytical validation is mandatory prior to initiating preclinical trials. Impurities in commercial lots can induce off-target cytotoxicity or false-positive enzyme inhibition data.
PX1 Research enforces strict quality assurance protocols for all analytical reference standards and research chemicals. Every lot of 5-Amino-1MQ manufactured in USA-based, GMP-compliant facilities undergoes rigorous third-party testing in ISO 17025 accredited analytical laboratories.
Quality standards require dual-verification:
1. High-Performance Liquid Chromatography (HPLC): Confirms chemical purity equal to or exceeding 98.0%, ensuring the absence of degradation products or related isomers.
2. Mass Spectrometry (MS/ESI): Verifies precise molecular weight and structural identity against theoretical mass spectrum values.
3. Endotoxin Testing: Quantitative Chromogenic LAL assays ensure endotoxin levels remain strictly below <0.01 EU/mg, protecting cell cultures and animal models from inflammatory artifacts.
Every batch includes a downloadable, lot-specific Certificate of Analysis (COA) containing raw spectra and chromatograms, supporting full experimental reproducibility.
What is the primary mechanism of 5-Amino-1MQ in preclinical studies?
5-Amino-1MQ acts as a membrane-permeable, substrate-competitive inhibitor of nicotinamide N-methyltransferase (NNMT). By inhibiting NNMT, it prevents the methylation of nicotinamide, thereby increasing intracellular NAD+ levels and activating SIRT1-mediated metabolic pathways.
How does 5-Amino-1MQ affect intracellular NAD+ levels?
NNMT converts nicotinamide into 1-methylnicotinamide, removing it from the cellular NAD+ salvage pathway. By blocking NNMT, 5-Amino-1MQ preserves nicotinamide, allowing NAMPT to convert it into NAD+ precursors and elevating total NAD+ availability.
What analytical methods verify the purity of PX1 5-Amino-1MQ?
PX1 Research verifies 5-Amino-1MQ purity through reverse-phase HPLC (requiring >=98% purity), Electrospray Ionization Mass Spectrometry (ESI-MS) for mass confirmation, and LAL chromogenic assays to verify low endotoxin levels (<0.01 EU/mg).
What solvent is recommended for dissolving 5-Amino-1MQ in cell culture protocols?
5-Amino-1MQ reconstitutes efficiently in anhydrous DMSO (up to 20-50 mg/mL). Stock solutions in DMSO should be diluted into aqueous culture media to maintain a final DMSO concentration <=0.1% to prevent solvent-mediated cell toxicity.
How does 5-Amino-1MQ compare to peptide metabolic regulators like MOTS-c?
5-Amino-1MQ is an intracellular small-molecule enzyme inhibitor targeting NNMT and NAD+ metabolism. MOTS-c is a mitochondrial-derived peptide that translocates to the nucleus to regulate folate metabolism and activate AMPK. They operate via distinct molecular cascades.
What are the recommended laboratory storage conditions for 5-Amino-1MQ?
Lyophilized or crystalline 5-Amino-1MQ powder should be stored desiccated at -20 deg C or -80 deg C, protected from light. Reconstituted DMSO stock solutions should be stored in single-use aliquots at -80 deg C to prevent degradation.
Is 5-Amino-1MQ approved for human consumption or clinical therapy?
No. 5-Amino-1MQ is sold strictly as a laboratory research chemical for in vitro and preclinical experimental applications. It is not approved for human or animal therapeutic, diagnostic, or clinical use.
Where are PX1 Research compounds synthesized and shipped from?
All PX1 Research compounds are manufactured in US-based GMP-compliant facilities and ship directly from fulfillment centers located in California and Arizona, with same-day dispatch for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.